-- Samsung Electronics (KRX:005930) posted first-quarter operating income of 57.23 trillion won, up 756% from 6.69 trillion won a year earlier, according to a Thursday filing with the Korea Exchange.
The South Korean chipmaker's sales jumped 69% year over year to an all-time quarterly high of 133.87 trillion won from 79.14 trillion won.
Zhejiang Sanhua Intelligent Controls (SHE:002050) posted first-quarter attributable net profit of 927.6 million yuan, up 2.7% from 903.4 million yuan the previous year.Earnings per share declined to 0.22 yuan from 0.24 yuan, according to a Thursday filing with the Shenzhen bourse.Operating revenue climbed 1.4% year over year to 7.77 billion yuan from 7.67 billion yuan.Shares of the refrigeration and air-conditioning components maker were up 5% in recent trade.
Singapore's total employment grew by 5,000 during the first quarter of the year, compared to 2,300 a year earlier, marking the 18th consecutive quarter of job growth, according to preliminary data from the Ministry of Manpower released Thursday.Despite the year-on-year growth, employment was down from the 17,700 growth in the previous quarter, mainly due to broad-based weakening in the labor market.Overall, unemployment rates edged up to 2.1% in March, compared to 2.0% in December 2025.Retrenchments remained low at 1.5 per 1,000 employees in Q1, unchanged from Q4, 2025.The ministry expects labor market to remain tight and expand in the second quarter. However, the share of firms expecting to hire in the next three months fell to 44.6% in March, compared to 54.6% in February.
Clarity Pharmaceuticals (ASX:CU6) will start a registrational phase 3 trial of copper-64-SARTATE in neuroendocrine tumors, following a successful end-of-phase meeting with the US Food and Drug Administration (FDA), according to a Thursday Australian bourse filing.The company plans to recruit around 70 participants for the trial.Clarity is also conducting recruitment for its registrational phase 3 positron emission tomography imaging trial of participants with high-risk prostate cancer prior to radical prostatectomy using copper-64-SAR-bisPSMA in the US and Australia, per the filing. It plans to recruit around 383 participants.The trial will assess the diagnostic performance of copper-64-SAR-bisPSMA positron emission tomography in detecting prostate cancer within the pelvic lymph nodes, the filing said.Clarity Pharmaceuticals' shares fell nearly 2% in recent trading on Thursday.